ABOUT BAPA

Our Mission

Advocate – Educate – Communicate

We strive to organize Bangladeshi-American Pharmacists in a strong and professional platform so they can be more successful in their career and have a fulfilling experience in this country. We work to get the members involved in the socio-political process that determines their future. We hope to motivate everyone to contribute their time and talent to the betterment of the pharmacy profession here at home and in Bangladesh.

Specifically, the purpose of the organization is to foster cooperation and collaboration among Bangladeshi pharmacists residing in North America; to build and maintain relations with other pharmacists’ associations in North America, to support the profession of pharmacy in Bangladesh and in North America; to support and encourage the development of Pharmaceutical Science in Bangladesh; to develop and conduct programs for maintaining and improving the professional standards; to promote welfare of members’ families in case of need; to protect the professional interests of members of the Association.

Our Sponsors

Silver Sponsor

Silver Sponsor

Silver Sponsor

Pharmaceutical News

  • A new method for efficient synthesis of anti-cancer drugs
    on December 6, 2024 at 9:00 am

    The Horner-Wadsworth-Emmons (HWE) reaction is a fundamental reaction in organic chemistry, widely used to create conjugated carbonyl compounds. Conjugated carbonyl compounds are used in many industries for synthesizing perfumes, plastics, and pharmaceuticals and are also involved in biological processes. Consequently, methods for improving HWE reactions are an active area of research. One potential application of HWE reactions is to develop (E)-isomers of conjugated carbonyl compounds that are useful for synthesizing chemicals called hynapene analogues with promising anti-cancer properties.

  • First single-dose medicine for P. vivax malaria prequalified by WHO and included in WHO Guidelines
    on December 5, 2024 at 9:00 am

    GSK plc (LSE/NYSE: GSK) and Medicines for Malaria Venture (MMV) announced that the World Health Organization (WHO) has awarded prequalification to tafenoquine, the first single-dose medicine for the prevention of relapse of Plasmodium vivax (P. vivax) malaria. Tafenoquine, co-administered with chloroquine, is now also included in WHO's updated Guidelines for malaria, in South America, marking the first time the medicine has been recommended by WHO. This milestone is a significant step toward closing the treatment gap for P. vivax malaria.

  • Unexpected discovery revives abandoned breast cancer treatment
    on December 4, 2024 at 9:00 am

    A new study led by Lund University in Sweden has solved a years-old mystery: which patients with aggressive breast cancer are helped by a targeted cancer treatment that had been under development but was shelved. The study is important since it brings hope that the development of the drug can continue and that it will make it all the way to these patients. Despite the efforts of the North American researchers, many years of research and development and millions of dollars spent, a medicine named ganitumab that had shown promising results against breast cancer in animal trials was shelved.

  • Gluing treatment to cancer
    on December 3, 2024 at 9:00 am

    Treatment for more advanced and difficult-to-treat head and neck cancers can be improved with the addition of polyvinyl alcohol (PVA), the same ingredient used in children's glue. Researchers found that combining PVA with a boron-containing compound, D-BPA, improved the effects of a type of radiation therapy for cancer, compared to currently clinically used drugs. The PVA made the drug more selective of tumor cells and prolonged drug retention, helping to spare healthy cells from unnecessary radiation damage.

  • Common heart drug may slow progression of Huntington's disease
    on December 2, 2024 at 9:00 am

    A common heart drug may slow the progression of Huntington's disease (HD), according to a new study by University of Iowa Health Care researchers. Using clinical information from a large, observational database of over 21,000 people with HD, the UI team found that the use of beta-blocker drugs - commonly used to treat heart and blood pressure issues - was associated with both a significantly later onset of HD symptoms for people in the pre-symptomatic stages, and a slower rate of symptom worsening for those with symptoms.